Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.71 |
| ▸ | CTSS | P25774 | 5/20 | 0.71 |
| ▸ | PPARA | Q07869 | 5/20 | 0.62 |
| ▸ | PPARG | P37231 | 4/20 | 0.62 |
| ▸ | ACE | P12821 | 1/20 | 0.60 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181807 | 1.00 | CTSK (0.71) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL181808 | 1.00 | CTSK (0.71) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL8238590 | 0.95 | PPARA (0.70) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL13744253 | 0.95 | PPARA (0.70) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL344068 | 0.93 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL22651626 | 0.93 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL19605638 | 0.93 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL2781406 | 0.92 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL1374859 | 0.92 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE | |
| SCHEMBL346311 | 0.92 | CTSK (0.63) | CTSKCTSSPPARAPPARGACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298056-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-10-18 | — | — | US | claimed |
| WO-2016170544-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | claimed |
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-07 | — | — | US | disclosed |
| EP-3788039-B1 | FACTOR XIIA INHIBITORS | UNIV LEEDS INNOVATIONS LTD (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4638415-A1 | BIS-ESTER AND AMIDE CATIONIC LIPIDS | Sanofi Pasteur Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-16 | — | — | US | disclosed |
| US-12383560-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-5153226-A | Administering as anticholesterol agents, for atherosclerosis | WARNER-LAMBERT COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| WO-1992016524-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| US-5149795-A | Fungicides | BAYER AG (DE) | 1992-09-22 | — | — | US | disclosed |
| EP-0478362-A2 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| US-5019560-A | Method for treating fungal infections with nikkomycin derivatives | BAYER AG (DE) | 1991-05-28 | — | — | US | disclosed |
| EP-0415413-A1 | Acat inhibitors | WARNER-LAMBERT COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
| EP-0367954-A1 | Nikkomycin derivatives, antimycotic compositions of nikkomycin derivatives and azole antimycotics | BAYER AG (DE) | 1990-05-16 | — | — | EP | disclosed |
| WO-1990000399-A1 | RETROVIRAL PROTEASE BINDING PEPTIDES | SMITHKLINE BECKMAN CORPORATION (US) | 1990-01-25 | — | — | WO | disclosed |
| EP-0352000-A2 | Retroviral protease binding peptides | SMITHKLINE BEECHAM CORPORATION (US) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125363-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | CTSK 4042/4885CTSS 3662/4885PPARA 2634/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | CTSK 4661/4885CTSS 4022/4885PPARA 2794/4885 |
| US-12383560-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | CTSK 2434/4885CTSS 2010/4885PPARA 1483/4885 |
| US-20180298056-A1 | PROCESS FOR THE PREPARATION OF (2S)-N-((S)-1-((S)-4-METHYL-1-((R)-2-METHYL OXIRAN-2-YL)-1-OXOPENTAN-2-YLCARBAMOYL)-2-PHENYLETHYL)-2-((S)-2-(2-MORPHOLINO ACETAMIDO)-4-PHENYLBUTANAMIDO)-4-METHYLPENTANAMIDE | OPRL1, OPRM1, ADRA1D | CTSK 4506/4885CTSS 3324/4885PPARA 3374/4885 |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | CTSK 1101/4885CTSS 640/4885PPARA 4669/4885 |
| US-12415798-B2 | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SCNN1G | CTSK 2963/4885CTSS 3812/4885PPARA 4410/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | CTSK 303/4885CTSS 714/4885PPARA 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.